HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 297 filers reported holding HAEMONETICS CORP in Q3 2023. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,077,929 | -7.1% | 112,502 | -11.7% | 0.00% | 0.0% |
| Q2 2023 | $10,845,559 | +12.6% | 127,385 | +9.5% | 0.00% | 0.0% |
| Q1 2023 | $9,629,369 | +4.0% | 116,367 | -1.1% | 0.00% | 0.0% |
| Q4 2022 | $9,255,453 | +6.1% | 117,679 | -0.2% | 0.00% | 0.0% |
| Q3 2022 | $8,725,000 | +13.0% | 117,858 | -0.5% | 0.00% | 0.0% |
| Q2 2022 | $7,722,000 | +3.7% | 118,467 | +0.6% | 0.00% | +33.3% |
| Q1 2022 | $7,444,000 | +19.0% | 117,748 | -0.2% | 0.00% | +50.0% |
| Q4 2021 | $6,257,000 | -24.9% | 117,974 | -0.0% | 0.00% | -33.3% |
| Q3 2021 | $8,331,000 | +3.9% | 118,025 | -1.9% | 0.00% | 0.0% |
| Q2 2021 | $8,018,000 | -16.0% | 120,317 | +40.0% | 0.00% | -25.0% |
| Q1 2021 | $9,541,000 | -5.5% | 85,946 | +1.1% | 0.00% | -20.0% |
| Q4 2020 | $10,095,000 | +33.9% | 85,011 | -1.6% | 0.01% | +25.0% |
| Q3 2020 | $7,538,000 | -14.8% | 86,400 | -12.5% | 0.00% | -20.0% |
| Q2 2020 | $8,846,000 | -52.0% | 98,770 | -46.6% | 0.01% | -61.5% |
| Q1 2020 | $18,439,000 | +4.9% | 185,020 | +20.9% | 0.01% | +30.0% |
| Q4 2019 | $17,585,000 | -17.7% | 153,050 | -9.7% | 0.01% | -23.1% |
| Q3 2019 | $21,369,000 | +0.6% | 169,410 | -4.0% | 0.01% | 0.0% |
| Q2 2019 | $21,239,000 | +37.3% | 176,490 | -0.2% | 0.01% | +30.0% |
| Q1 2019 | $15,466,000 | -14.8% | 176,790 | -2.6% | 0.01% | -23.1% |
| Q4 2018 | $18,162,000 | +28.2% | 181,530 | +46.8% | 0.01% | +44.4% |
| Q3 2018 | $14,164,000 | +23.2% | 123,620 | -3.6% | 0.01% | +12.5% |
| Q2 2018 | $11,495,000 | +31.2% | 128,180 | +7.0% | 0.01% | +33.3% |
| Q1 2018 | $8,762,000 | +87.1% | 119,770 | +48.6% | 0.01% | +100.0% |
| Q4 2017 | $4,682,000 | +29.8% | 80,606 | +0.3% | 0.00% | 0.0% |
| Q3 2017 | $3,607,000 | +13.6% | 80,390 | 0.0% | 0.00% | +50.0% |
| Q2 2017 | $3,175,000 | -3.8% | 80,390 | -1.2% | 0.00% | -33.3% |
| Q1 2017 | $3,302,000 | +0.9% | 81,390 | -0.0% | 0.00% | 0.0% |
| Q4 2016 | $3,272,000 | +11.0% | 81,401 | 0.0% | 0.00% | +50.0% |
| Q3 2016 | $2,948,000 | +25.0% | 81,401 | +0.0% | 0.00% | 0.0% |
| Q2 2016 | $2,359,000 | -11.2% | 81,390 | +7.1% | 0.00% | 0.0% |
| Q1 2016 | $2,658,000 | +12.0% | 75,990 | +3.2% | 0.00% | 0.0% |
| Q4 2015 | $2,374,000 | -26.9% | 73,640 | -26.7% | 0.00% | -33.3% |
| Q3 2015 | $3,249,000 | -21.9% | 100,531 | -0.1% | 0.00% | 0.0% |
| Q2 2015 | $4,161,000 | -15.3% | 100,600 | -8.0% | 0.00% | -25.0% |
| Q1 2015 | $4,910,000 | +20.0% | 109,300 | 0.0% | 0.00% | +33.3% |
| Q4 2014 | $4,090,000 | +4.7% | 109,300 | -2.3% | 0.00% | 0.0% |
| Q3 2014 | $3,908,000 | -1.0% | 111,900 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $3,948,000 | +5.1% | 111,900 | -2.9% | 0.00% | 0.0% |
| Q1 2014 | $3,757,000 | -20.9% | 115,285 | +2.3% | 0.00% | -25.0% |
| Q4 2013 | $4,748,000 | -0.4% | 112,700 | -5.7% | 0.00% | -20.0% |
| Q3 2013 | $4,766,000 | -3.5% | 119,500 | 0.0% | 0.01% | 0.0% |
| Q2 2013 | $4,941,000 | – | 119,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |